ラロキシフェン塩酸塩
ラロキシフェン塩酸塩 物理性質
- 融点 :
- 250-253°C
- 貯蔵温度 :
- 2-8°C
- 溶解性:
- DMSO: 28 mg/mL、可溶
- 外見 :
- 個体
- 色:
- ライトイエロー
- 極大吸収波長 (λmax):
- 286nm(lit.)
- Merck :
- 14,8098
- BCS Class:
- 2
- InChIKey:
- BKXVVCILCIUCLG-UHFFFAOYSA-N
- SMILES:
- C1(C(=O)C2C=CC(OCCN3CCCCC3)=CC=2)C2C=CC(O)=CC=2SC=1C1C=CC(O)=CC=1.Cl
- CAS データベース:
- 82640-04-8(CAS DataBase Reference)
安全性情報
- リスクと安全性に関する声明
- 危険有害性情報のコード(GHS)
絵表示(GHS) |
|
注意喚起語 |
警告 |
危険有害性情報 |
コード |
危険有害性情報 |
危険有害性クラス |
区分 |
注意喚起語 |
シンボル |
P コード |
H351 |
発がんのおそれの疑い |
発がん性 |
2 |
警告 |
|
P201, P202, P281, P308+P313, P405,P501 |
|
注意書き |
P201 |
使用前に取扱説明書を入手すること。 |
P202 |
全ての安全注意を読み理解するまで取り扱わないこ と。 |
P280 |
保護手袋/保護衣/保護眼鏡/保護面を着用するこ と。 |
P308+P313 |
暴露または暴露の懸念がある場合:医師の診断/手当てを 受けること。 |
P405 |
施錠して保管すること。 |
P501 |
内容物/容器を...に廃棄すること。 |
|
メーカー |
製品番号 |
製品説明 |
CAS番号 |
包装 |
価格 |
更新時間 |
購入 |
富士フイルム和光純薬株式会社(wako)
|
W01COBQA-8277 |
Raloxifene HCl |
82640-04-8 |
1g |
¥12500 |
2024-03-01 |
購入 |
富士フイルム和光純薬株式会社(wako)
|
W01COBQA-8277 |
Raloxifene HCl |
82640-04-8 |
5g |
¥40000 |
2024-03-01 |
購入 |
東京化成工業
|
R0109 |
ラロキシフェン塩酸塩 >98.0%(HPLC)(T)
Raloxifene Hydrochloride
>98.0%(HPLC)(T) |
82640-04-8 |
1g |
¥8900 |
2024-03-01 |
購入 |
東京化成工業
|
R0109 |
ラロキシフェン塩酸塩 >98.0%(HPLC)(T)
Raloxifene Hydrochloride
>98.0%(HPLC)(T) |
82640-04-8 |
5g |
¥29500 |
2024-03-01 |
購入 |
Sigma-Aldrich Japan
|
PHR1852 |
ラロキシフェン 塩酸塩 Pharmaceutical Secondary Standard; Certified Reference Material
Raloxifene Hydrochloride Pharmaceutical Secondary Standard; Certified Reference Material |
82640-04-8 |
500mg |
¥21900 |
2024-03-01 |
購入 |
ラロキシフェン塩酸塩 化学特性,用途語,生産方法
効能
骨粗鬆症治療薬, 選択的エストロゲン受容体モジュレータ (SERM)
商品名
エビスタ (日本イーライリリー)
説明
Raloxifene was launched as Evista in the US for the prevention of
postmenopausal osteoporosis. It is noteworthy that this molecule was formerly
under development as keoxifene for breast cancer and prostatic hypertrophy.
Raloxifene can be prepared by acylation of 6-methoxy-2-(4-methoxyphenyl)
benzothiophene followed by simultaneous demethylation of both methoxy
groups. Raloxifen is a selective estrogen receptor modulator, exerting antiestrogenic
action on certain tissues (breast) and also estrogenic action on bone
metabolism or serum lipids. In normal early postmenopausal women, 200 mg
daily produced a trend towards suppression of estrogen effects. Raloxifen
impeded bone loss in osteoporosis. A two-year study in postmenopausal women
with an increased risk for osteoporosis showed that Raloxifen markedly
prevented non-traumatic vertebral fractures. Results of several clinical studies
demonstrated that Raloxifen appreciably reduced the risk of developing breast
cancer. Moreover, it had favourable effect on lipid profiles without having the
potential side-effects of estrogen-based therapies. Several extensions for
different uses of this molecule are planned, for example growth disorder,
obesity, colon tumor and skin atrophy. No serious drug-related events have
been reported in the limited number of clinical trials.
化学的特性
Light-Yellow Solid
使用
Raloxifene hydrochloride can be used as a nonsteroidal, selective estrogen receptor modulator (SERM). Antiosteoporotic.
定義
ChEBI: A hydrochloride salt resulting from the reaction of equimolar amounts of raloxifene and hydrogen chloride.
一般的な説明
Pharmaceutical secondary standards for application in quality control provide pharma laboratories and manufacturers with a convenient and cost-effective alternative to the preparation of in-house working standards
ラロキシフェン塩酸塩 上流と下流の製品情報
原材料
準備製品
ラロキシフェン塩酸塩 生産企業
Global( 481)Suppliers
ラロキシフェン塩酸塩 スペクトルデータ(1HNMR)
82640-04-8(ラロキシフェン塩酸塩)キーワード:
- 82640-04-8
- RALOXIFENE HCL
- Raloxifene hydrochloride,Keoxifene hydrochloride, LY 156758, [6-Hydroxy-2-(4-hydroxyphenyl)benzo[b]thien-3-yl][4-[2-(1-piperidinyl)ethoxy]phenyl]methanone hydrochloride
- Raloxifene Hydrochloride (200 mg)
- 2-(4-hydroxyphenyl)-3-({4-[2-(piperidin-1-yl)ethoxy]phenyl}carbonyl)-1-benzothiophen-6-ol hydrochloride
- (6-Hydroxy-2-(4-hydroxyphenyl)benzo[b]thiophen-3-yl)(4-(2-(piperidin-1-yl)ethoxy)phenyl)Methanone hydrochloride
- Evista(Raloxifene Hydrochloride
- (6-Hydroxy-2-(4-hydroxyphenyl)benzo[b]thiophen-3-yl)-(4-(2-(piperidin-1-yl)ethoxy)phenyl)methanon
- [6-hydroxy-2-(4-hydroxyphenyl)benzo[b]thien-3-yl][4-[2-(1-piperidinyl)ethoxy]phenyl]-methanone,hydrochloride (1:1)
- LY156758 (Keoxifene) HCl
- Evista (Raloxifene HCl)
- Methanone,[6-hydroxy-2-(4-hydroxyphenyl)benzo[b]thien-3-yl][4-[2-(1-piperidinyl)ethoxy]phenyl]-,hydrochloride (1:1)
- (6-Hydroxy-2-(4-hydroxyphenyl)benzo[b]thiophen-3-yl)-(4-(2-(piperidin-1-yl)ethoxy)phenyl)metha
- RALOXIFENE HYDROCHLORIDE
- KEOXIFENE
- KEOXIFENE HYDROCHLORIDE
- LY 139481
- AKOS 92138
- ly156758
- methanone,(6-hydroxy-2-(4-hydroxyphenyl)benzo(b)thien-3-yl)(4-(2-(1-piperidin
- [6-HYDROXY-2-(4-HYDROXYPHENYL)BENZO[B]THIEN-3-YL][4-[2-(1-PIPERIDINYL)ETHOXY]PHENYL]-METHANONE HYDROCHLORIDE
- [6-Hydroxy-2-(4-Hydroxyphenyl) benzo[b]thien-3-yl]
- RALOXIFENEHYDROCHLORIDE(SUBJECTTOPATENTFREE)
- Keoxifene hydrochloride, LY 156758, [6-Hydroxy-2-(4-hydroxyphenyl)benzo[b]thien-3-yl][4-[2-(1-piperidinyl)ethoxy]phenyl]methanone hydrochloride
- 6-Hydroxy-2-(4-hydroxyphenyl)benzo[b]thien-3-yl][4-[2-(1-piperidinyl) ethoxy]phenyl]methanone HCl
- Raloxifene Hydrochloride Tablets
- LY156758 hydrochloride
- CS-127
- LY139481 hydrochloride
- Raloxifene hydrochloride,>98%
- [6-Hydroxy-2-(4-hydroxyphenyl)benzo[b]thiophen-3-yl][4-[2-(1-piperidinyl)ethoxy]phenyl]methanone Hydrochloride
- ラロキシフェン塩酸塩
- [6-ヒドロキシ-2-(4-ヒドロキシフェニル)ベンゾ[b]チオフェン-3-イル][4-[2-(1-ピペリジニル)エトキシ]フェニル]メタノン塩酸塩
- ラロキシフェン 塩酸塩
- ラロキシフェン塩酸塩 (JAN)
- 塩酸ラロキシフェン
- エビスタ
- [6-ヒドロキシ-2-(4-ヒドロキシフェニル)ベンゾ[b]チオフェン-3-イル][4-[2-(1-ピペリジニル)エトキシ]フェニル]メタノン・塩酸塩